5395232025-10-012025-12-315395232025-04-012025-12-315395232025-10-012025-12-31in-capmkt:OtherExpenses1Member5395232025-04-012025-12-31in-capmkt:OtherExpenses1Member5395232025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25395232025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-132026-01-23INRMillionsQuarterlyThird quarterSingle segmentThe Company is exclusively engaged in pharmaceutical business2026-02-1311:00:002026-02-1313:45:00Not applicablefalsefalseNo defaults on loans and debt securities2025-10-012025-12-31UnauditedStandalone249127000001315300000262280000005875100000113100000015670000048558000001551000006091000006002000000187848000007443200000-38170000070615000001243900000-4038000008401000000622140000000006221400000-957000006125700000239100000252.0352.030052.0352.031) The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). <BR> <BR> 2) The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 12 February 2026 and subsequently approved by the Board of Directors at its meeting held on 13 February 2026. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2025. <BR> <BR> 3) The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited. <BR> <BR> During the earlier periods, the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". <BR> <BR> Key financial information of Discontinued Operations: <BR> <BR> Quarter ended 31.12.2025 <BR> Total Income : NIL <BR> Total expenses : NIL <BR> Profit before tax : NIL <BR> Total tax expense : NIL <BR> Net profit for the period after tax : NIL <BR> <BR> Quarter ended 30.09.2025 <BR> Total Income : 5,622.8 <BR> Total expenses : 4,653.3 <BR> Profit before tax : 969.5 <BR> Total tax expense : 338.8 <BR> Net profit for the period after tax : 630.7 <BR> <BR> Quarter ended 31.12.2024 <BR> Total Income : 4,880.4 <BR> Total expenses : 4,159.7 <BR> Profit before tax : 720.7 <BR> Total tax expense : 251.8 <BR> Net profit for the period after tax : 468.9 <BR> <BR> Nine months ended 31.12.2025 <BR> Total Income : 9,181.0 <BR> Total expenses : 7,690.5 <BR> Profit before tax : 1,490.5 <BR> Total tax expense : 520.8 <BR> Net profit for the period after tax : 969.7 <BR> <BR> Nine months ended 31.12.2024 (*Note: The figures for the nine months ended 31 December 2025 are not comparable with those of the corresponding period, as they reflect carved-out results up to 30 September 2025, the date on which the generic business was transferred to Alkem Wellness Limited.) <BR> Total Income : 13,784.4 <BR> Total expenses : 11,630.7 <BR> Profit before tax : 2,153.7 <BR> Total tax expense : 752.6 <BR> Net profit for the period : 1,401.1 <BR> <BR> Year ended 31.03.2025 <BR> Total Income : 18,974.9 <BR> Total expenses : 16,036.4 <BR> Profit before tax : 2,938.5 <BR> Total tax expense : 1,026.8 <BR> Net profit for the period : 1,911.7 <BR> <BR> 4) Exceptional items include: <BR> <BR> 1) The Government of India notified the four Labour Codes which are effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. <BR> <BR> The incremental impact basis preliminary analysis of Rs. 381.7 million is classified and disclosed as an exceptional item in the results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate financial impact on the basis of such developments as needed. <BR> <BR> 2) The Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility. The said facility had been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to Rs. 142.9 million had been classified and disclosed as an exceptional item in the results for the nine months ended 31 December 2025. <BR> <BR> 5) The Board of Directors at its meeting held on 13 February 2026 have declared an interim dividend of Rs. 43 (Rupees Forty Three only) per equity share (2150 % on the face value of Rs. 2 each) for the financial year ending 31 March 2026. <BR> <BR> 6) The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.2025-04-012025-12-31UnauditedStandalone74054700000349480000077549500000177047000003194500000210000000141617000004105000001783900000179801000005544540000022104100000-238800000218653000003572900000-138820000021847000000196806000001490500000520800000969700000020650300000-138800000205115000002391000002164.6164.68.118.11172.71172.71Other Expenses6002000000Other Expenses17980100000In respect of continuing operations:-147000000In respect of discontinued operations:0-147000000In respect of continuing operations:-209700000In respect of discontinued operations:-3600000-213300000-51300000-74500000-95700000-138800000